Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc provides a detailed overview of its global medical technology business, risks, and strategic priorities. The company operates across three main portfolios — Cardiovascular, Neuroscience, and Medical Surgical — offering devices from cardiac rhythm management and transcatheter valves to neuromodulation, surgical robotics, and acute care monitoring.
Medtronic highlights a major portfolio shift: its Diabetes Business is being separated into MiniMed Group, Inc., which completed an initial public offering in March 2026. The report also emphasizes heavy investment in R&D, expanded use of data, AI and automation, and a broad intellectual property base in an industry with intense competition and frequent litigation.
The company underscores human capital as a key asset, with over 95,000 employees, strong pay-equity metrics, and extensive learning programs. It also devotes substantial discussion to regulatory, reimbursement, data-privacy, trade, and environmental frameworks that shape how its products are developed, approved, manufactured, and paid for worldwide, including EU MDR, GDPR, and evolving AI regulation.
Medtronic plc executive Harry Skip Kiil reported selling Ordinary Shares in two open-market transactions. On June 8, 2026, he sold a total of 4,189 Medtronic Ordinary Shares in the open market at prices around $80.44–$80.45 per share. These are non-derivative transactions reported as direct ownership and represent routine insider sales rather than option exercises or gifts.
Medtronic plc executive Harry Skip Kiil reported a routine tax-withholding share disposition tied to equity compensation. On the transaction date, 6,817 Ordinary Shares were withheld at $83.32 per share to cover taxes upon settlement of performance-vesting restricted stock units that vested on April 24, 2026. After this non-market transaction, he directly holds 41,416 Medtronic Ordinary Shares.
Medtronic plc Chairman and CEO Geoffrey Martha reported a routine tax-related share disposition. On settlement of performance-vesting restricted stock units that vested on April 24, 2026, 41,936 ordinary shares were withheld to cover tax obligations at $83.32 per share. After this withholding, Martha directly holds 301,163 ordinary shares, and the filing does not show any open-market buying or selling.
Medtronic plc executive Michael Marinaro reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and on June 4, 2026, 7,471 Ordinary Shares were withheld at $83.32 per share to cover associated tax obligations. After this withholding, he directly holds 63,122 Ordinary Shares.
Medtronic plc senior vice president and Chief HR Officer Walter Matthew R. reported a routine tax-related share disposition. On June 4, 2026, 2,840 Ordinary Shares at $83.32 per share were withheld to cover taxes due on performance-vesting restricted stock units that vested on April 24, 2026. Following this withholding, he directly holds 38,689 Ordinary Shares.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and 237 ordinary shares were withheld to cover taxes at a value of $83.32 per share. After this withholding, she directly holds 14,737 ordinary shares of Medtronic, indicating a small adjustment to her equity position tied to compensation rather than an open-market sale.
Medtronic plc reported strong Q4 and fiscal 2026 results with its fastest annual revenue growth in 10 years. Q4 revenue reached $9.807 billion, up 9.9% as reported and 6.6% organic, with GAAP EPS of $0.96 and non-GAAP EPS of $1.55, both ahead of guidance.
For FY26, revenue was $36.364 billion, up 8.4% reported and 5.8% organic. GAAP EPS was $3.73, up 3.3%, while non-GAAP EPS was $5.53, up 0.7%, as operating margin was flat on a GAAP basis and modestly lower on a non-GAAP basis.
Cardiovascular revenue grew 12.0% for the year, Neuroscience 4.5%, Medical Surgical 4.9%, and Diabetes 12.9% reported. Free cash flow was $5.426 billion, and the quarterly dividend was raised to $0.72 per share, marking the 49th consecutive annual dividend increase.
Looking to FY27, Medtronic guides to 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS of $5.90 to $6.00, implying 6.7% to 8.5% EPS growth, including the impact of a 53rd week and full-year Diabetes business consolidation.
Medtronic plc reported strong Q4 and fiscal 2026 results with its fastest annual revenue growth in 10 years. Q4 revenue reached $9.807 billion, up 9.9% as reported and 6.6% organic, with GAAP EPS of $0.96 and non-GAAP EPS of $1.55, both ahead of guidance.
For FY26, revenue was $36.364 billion, up 8.4% reported and 5.8% organic. GAAP EPS was $3.73, up 3.3%, while non-GAAP EPS was $5.53, up 0.7%, as operating margin was flat on a GAAP basis and modestly lower on a non-GAAP basis.
Cardiovascular revenue grew 12.0% for the year, Neuroscience 4.5%, Medical Surgical 4.9%, and Diabetes 12.9% reported. Free cash flow was $5.426 billion, and the quarterly dividend was raised to $0.72 per share, marking the 49th consecutive annual dividend increase.
Looking to FY27, Medtronic guides to 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS of $5.90 to $6.00, implying 6.7% to 8.5% EPS growth, including the impact of a 53rd week and full-year Diabetes business consolidation.
Medtronic plc reported strong Q4 and fiscal 2026 results with its fastest annual revenue growth in 10 years. Q4 revenue reached $9.807 billion, up 9.9% as reported and 6.6% organic, with GAAP EPS of $0.96 and non-GAAP EPS of $1.55, both ahead of guidance.
For FY26, revenue was $36.364 billion, up 8.4% reported and 5.8% organic. GAAP EPS was $3.73, up 3.3%, while non-GAAP EPS was $5.53, up 0.7%, as operating margin was flat on a GAAP basis and modestly lower on a non-GAAP basis.
Cardiovascular revenue grew 12.0% for the year, Neuroscience 4.5%, Medical Surgical 4.9%, and Diabetes 12.9% reported. Free cash flow was $5.426 billion, and the quarterly dividend was raised to $0.72 per share, marking the 49th consecutive annual dividend increase.
Looking to FY27, Medtronic guides to 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS of $5.90 to $6.00, implying 6.7% to 8.5% EPS growth, including the impact of a 53rd week and full-year Diabetes business consolidation.